Senior Scientist, Protein Engineering (Phage Display) at Abata Therapeutics

San Diego, California, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

BiotechnologyIndustries

Requirements

Ph.D. in Molecular Biology, Biochemistry, Immunology, or related field with 2+ years of relevant industry or postdoctoral experience (or M.S. with 5+ years at Scientist level)
Hands-on experience with phage display platforms and antibody selection techniques
Strong understanding of antibody structure-function relationships and engineering strategies
Proficiency in molecular cloning, library construction, sequencing, and cell-based expression systems (bacterial, yeast, mammalian)
Experience with analytical tools such as ELISA, liquid handler automation, plate-based assays, flow cytometry, and affinity measurements (SPR, BLI)
Excellent problem-solving skills and ability to work independently and collaboratively
Highly proficient with Excel and molecular biology software (e.g., Geneious)

Responsibilities

Design, construct, and quality check phage display libraries used in peptide and antibody-based screening campaigns targeting diverse antigens
Screen synthetic and immune phage libraries for high-affinity binders
Characterize peptide and antibody candidates using biochemical, biophysical, and cell-based assays (e.g., ELISA, BLI, flow cytometry)
Develop directed evolution libraries and execute screening methods to optimize peptide and antibody formats for improved affinity, stability, and developability
Collaborate with protein sciences and protein engineering teams to produce and validate peptide and antibody candidates
Analyze sequencing data from phage pools and selected clones to identify lead candidates
Maintain accurate and detailed experimental records and present findings in internal meetings
Contribute to patent filings, publications, and regulatory documentation as needed
Mentor junior scientists and contribute to a culture of scientific excellence and innovation
Perform other duties as assigned

Skills

Phage Display

Antibody Discovery

Molecular Cloning

Library Design

Library Construction

DNA Sequencing

Cell-based Expression

ELISA

BLI

Flow Cytometry

Directed Evolution

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free